Clinical Trials Browser

Phase 2 × OTHER × Genitourinary × Clear all

NCT03436654 2026-04-22

Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT04917809 2026-04-22

A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer

Phase 2 Active not recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT06138496 2026-04-21

Cadonilimab Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC

Phase 2 Completed

Carcinoma, Renal Cell

NCT06284564 2026-04-21

A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)

Phase 2 Active not recruiting

Carcinoma, Renal Cell

NCT04393350 2026-04-20

Perioperative Lenvatinib With Pembrolizumab in Patients With Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma

Phase 2 Active not recruiting

18 enrolled 12 charts

Carcinoma, Renal Cell, Kidney Neoplasms

NCT06378866 2026-04-20

DIVINE

Phase 2 Recruiting

Prostatic Neoplasms

NCT02713269 2026-04-17

Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord

Phase 2 Active not recruiting

DermatologicGastrointestinalGenitourinaryHead & NeckSarcoma

Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Melanoma, Neoplasms, Unknown Primary, Sarcoma, Spinal Cord Compression, Thyroid Neoplasms

NCT05766371 2026-04-17

Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer

Phase 2 Recruiting

Prostatic Neoplasms

NCT07234981 2026-04-17

PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer

Phase 2 Recruiting

Prostatic Neoplasms

NCT07322263 2026-04-17

Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC

Phase 2 Recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell

NCT07535905 2026-04-17

REVIVE

Phase 2 Not yet recruiting

Hypogonadism, Prostatic Neoplasms

NCT06347705 2026-04-16

A Study of 2141-V11 in Combination With Standard Treatments in People With Prostate Cancer

Phase 2 Recruiting

Prostatic Neoplasms

NCT07110038 2026-04-16

DEPECA-1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab for Advanced and Metastatic Penile Carcinoma

Phase 2 Recruiting

Penile Squamous Cell Carcinoma (PSCC)

NCT07223424 2026-04-16

PSI-Immune

Phase 2 Recruiting

DermatologicGastrointestinalGenitourinaryGynecologicThoracic

Adenocarcinoma Of Esophagus, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Colitis, Ulcerative, Colonic Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma

NCT00814021 2026-04-15

Sunitinib in Treating Patients With Kidney Cancer That Has Spread to the Brain

Phase 2 Completed

CNSGenitourinary

Brain Neoplasms, Carcinoma, Renal Cell, Kidney Neoplasms, Neoplasm Metastasis

NCT00918775 2026-04-15

Follow-up After Metastasectomy in Patients With Kidney Cancer

Phase 2 Active not recruiting

Carcinoma, Renal Cell

NCT03575611 2026-04-15

Stereotactic Body Radiation Therapy in Treating Patients With Oligometastatic Renal Cell Carcinoma

Phase 2 Suspended

Carcinoma, Renal Cell

NCT03682289 2026-04-15

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

Phase 2 Recruiting

GastrointestinalGenitourinaryGynecologic

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Neoplasm Metastasis, Pancreatic Neoplasms, Endometrial Neoplasms

NCT03821792 2026-04-15

Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT04953104 2026-04-15

ARID1A and/or KDM6A Mutation and CXCL13 Expression

Phase 2 Active not recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT06638931 2026-04-15

ANTARES

Phase 2 Recruiting

BreastCNSEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckNETOther solid neoplasmSarcomaThoracic

Urachal adenocarcinoma, Urachal cancer, Fibrolamellar hepatocellular carcinoma, Secretory breast carcinoma, Carcinoma, Ovarian Epithelial, Adrenal Gland Neoplasms, Anus Neoplasms, Biliary Tract Neoplasms, Carcinosarcoma, Carcinoma, Adenoid Cystic, Fallopian Tube Neoplasms, Fibrosarcoma, Gallbladder Neoplasms, Granulosa Cell Tumor, Hemangiosarcoma, Leiomyosarcoma, Mesothelioma, Neuroblastoma, Parathyroid Neoplasms, Penile Neoplasms, Sarcoma, Sarcoma, Kaposi, Osteosarcoma, Thyroid Neoplasms, Trophoblastic Neoplasms, Urethral Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Hepatoblastoma, Endodermal Sinus Tumor, Neuroectodermal Tumors, Primitive, Cholangiocarcinoma, Sertoli-Leydig Cell Tumor, Neurofibrosarcoma, Hemangioblastoma, Neuroendocrine Tumors

NCT07111507 2026-04-15

A Study of Tarlatamab for People With Prostate Cancer

Phase 2 Recruiting

Prostatic Neoplasms

NCT07237269 2026-04-15

Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer

Phase 2 Recruiting

Prostatic Neoplasms

NCT01902680 2026-04-14

CURIEFOCALE

Phase 2 Completed

Prostatic Neoplasms

NCT05960578 2026-04-14

Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT06053658 2026-04-14

Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma

Phase 2 Recruiting

Carcinoma, Renal Cell

NCT02772588 2026-04-13

AASUR in High Risk Prostate Cancer

Phase 2 Completed

64 enrolled 7 charts

Prostatic Neoplasms

NCT03609216 2026-04-13

Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations

Phase 2 Active not recruiting

Infiltrating Bladder Urothelial Carcinoma

NCT04337580 2026-04-13

FASN

Phase 2 Recruiting

Neoplasms, Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT04842890 2026-04-13

Phase II Study of Pencil Beam Scanning Proton Stereotactic Body Radiation Therapy for Prostate Cancer

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT05239624 2026-04-13

Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer

Phase 2 Recruiting

Carcinoma, Transitional Cell

NCT05969496 2026-04-13

NEOPAX

Phase 2 Recruiting

Carcinoma, Renal Cell, Kidney Neoplasms

NCT06594926 2026-04-13

WOMBAT

Phase 2 Recruiting

Prostatic Neoplasms

NCT07220720 2026-04-13

POSLUMA® (18F-rhPSMA-7.3) PET-CT for PIRADS 2/3 Lesions

Phase 2 Recruiting

Prostatic Neoplasms

NCT03361735 2026-04-09

Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer

Phase 2 Active not recruiting

25 enrolled 10 charts

Prostate Adenocarcinoma

NCT05048212 2026-04-09

A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases

Phase 2 Recruiting

CNSGenitourinary

Brain Neoplasms, Carcinoma, Renal Cell

NCT07518979 2026-04-09

MH-Penile-002

Phase 2 Not yet recruiting

Penile Neoplasms

NCT00859781 2026-04-08

177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer

Phase 2 Active not recruiting

55 enrolled 11 charts

Prostatic Neoplasms

NCT05053152 2026-04-08

Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT05327686 2026-04-08

SAMURAI

Phase 2 Recruiting

Carcinoma, Renal Cell

NCT05406713 2026-04-08

Pembrolizumab in Muscle-invasive Bladder Cancer

Phase 2 Active not recruiting

Carcinoma, Transitional Cell

NCT05457699 2026-04-08

ANCHORProstate

Phase 2 Recruiting

Prostate Cancer Metastatic

NCT06392841 2026-04-08

HARMONY

Phase 2 Withdrawn

Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

NCT06503614 2026-04-08

ENHANCE

Phase 2 Recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT07354594 2026-04-08

ARREST

Phase 2 Not yet recruiting

Prostate Cancer Metastatic Castration-Resistant

NCT03093922 2026-04-07

A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer

Phase 2 Active not recruiting

Carcinoma, Transitional Cell

NCT04138628 2026-04-07

TOMBOLA

Phase 2 Active not recruiting

Urinary Bladder Neoplasms, Neoplasm Metastasis

NCT06632977 2026-04-07

PREDICT

Phase 2 Recruiting

Prostatic Neoplasms

NCT07515651 2026-04-07

MIDAS-SBRT

Phase 2 Not yet recruiting

Adenocarcinoma, Prostatic Neoplasms

NCT07516210 2026-04-07

ART-Hypo

Phase 2 Not yet recruiting

GastrointestinalGenitourinaryGynecologic

Uterine Cervical Neoplasms, Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Endometrial Neoplasms